Related content

Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer

By Simon George R   Begum Mubeena   Bepler Gerold  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 51-59

Future Medicine

Access to resources Recommend Favorite

Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care

By Laskin Janessa J  

Future Oncology, Vol. 1, Iss. 5, 2005-10 ,pp. : 619-623

Future Medicine

Access to resources Recommend Favorite

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer - a phase II trial

By Laack E.   Mende T.   Benk J.   Chemaissani A.   Scholtze J.   Lorenz C.   Niestroy A.   Dalhoff K.   Muller T.   Walter T.   Durk H.   Edler L.   Hossfeld D.K.  

European Journal of Cancer, Vol. 37, Iss. 5, 2001-03 ,pp. : 583-590

Elsevier

Access to resources Recommend Favorite

Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations

By Grossi F.  

memo - Magazine of European Medical Oncology, Vol. 1, Iss. 1, 2008-03 ,pp. : 13-16

Springer Publishing Company

Access to resources Recommend Favorite

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

By Arrieta Oscar  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 300-306

Humana Press, Inc

Access to resources Recommend Favorite